Jonathan Alsop
Jonathan Alsop has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Christian Cornelissen
Novartis Pharma GmbH, Nuremberg, Germany
2 shared publications Martin Scott
2 shared publicationsNiklas Bergvall
Novartis Pharma AG Basel Switzerland
2 shared publications- Stefan Viktor Vormfelde
Novartis Pharma GmbH, Nuremberg, Germany
2 shared publications - Tjalf Ziemssen
Universitätsklinikum Carl Gustav Carus
2 shared publications Catriona McBean
Water Safety New Zealand, Wellington, New Zealand
1 shared publication
Latest Publications
- Open Access
- 1 June 2022
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 11 (8) , 551-561
Matching-adjusted indirect comparison via a polynomial-based non-linear optimization method
Aim: To demonstrate the potential of fourth-order polynomials within a non-linear optimization framework for matching-adjusted indirect comparison (MAIC). Materials & methods: Simulated individual patient data were reweighted via fourth-order polynomials (polyMAIC) to match aggregate-level data across multiple baseline characteristics. The polyMAIC approach employed pre-specified matching tolerances and maximum allowable weights. Matching performance against aggregate-level targets was assessed, and also compared against the current industry-standard MAIC approach (Signorovitch). Results: The polyMAIC method matched aggregate-level targets within pre-specified tolerances. Effective sample sizes were either similar to or somewhat higher than those obtained from the Signorovitch method. Performance gains from polyMAIC tended to increase as matching complexity increased. Conclusion: PolyMAIC incorporates greater flexibility than the industry-standard MAIC approach and demonstrates matching potential.
- 1 June 2022
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 11 (8) , 551-561
Open AccessMatching-adjusted indirect comparison via a polynomial-based non-linear optimization method
Aim: To demonstrate the potential of fourth-order polynomials within a non-linear optimization framework for matching-adjusted indirect comparison (MAIC). Materials & methods: Simulated individual patient data were reweighted via fourth-order polynomials (polyMAIC) to match aggregate-level data across multiple baseline characteristics. The polyMAIC approach employed pre-specified matching tolerances and maximum allowable weights. Matching performance against aggregate-level targets was assessed, and also compared against the current industry-standard MAIC approach (Signorovitch). Results: The polyMAIC method matched aggregate-level targets within pre-specified tolerances. Effective sample sizes were either similar to or somewhat higher than those obtained from the Signorovitch method. Performance gains from polyMAIC tended to increase as matching complexity increased. Conclusion: PolyMAIC incorporates greater flexibility than the industry-standard MAIC approach and demonstrates matching potential.
- 31 December 2019
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 35 (S1) , 94-95
VP90 Which Matching Adjusted Indirect Comparison Method Is Best?
Introduction: Matching adjusted indirect comparison (MAIC) methods are extremely useful when conducting ITCs, as they reduce baseline imbalances between studies, particularly upon patient characteristics that are confounded with treatment. The standard approach when conducting MAIC is that proposed by Signorovitch et al. (2010). However, there are newer, and potentially better, methods available.Methods: Three different MAIC methods (Signorovitch, Entropy Balancing, Polynomial Weighting) were compared using multiple phase 3 RCTs conducted in Diabetic Retinal Edema. The matching ability of each method was assessed, alongside its ability to avoid large weights (i.e. avoiding high leverage), and maximise effective same size (ESS). Each method's overall ease of use and impact upon estimates of treatment effectiveness were also evaluated.Results: All methods were able to precisely match the aggregate level data. However, the Entropy Balancing and Polynomial Weighting both outperformed the Signorovitch method in terms of having the lowest maximum weights. The Polynomial Weighting provided the highest ESS. The Entropy Balancing method was arguably the most challenging to implement, whilst the Signorovitch method the least. The Polynomial Weighting method appears to provide the greatest flexibility to the user.Conclusions: Whilst the Signorovitch method has become almost synonymous with MAIC, the Entropy Balancing and Polynomial Weighting methods offer potentially superior performance. In the absence of head-to-head trial data, these new MAIC approaches should provide less biased and more precise estimates of comparative effectiveness – ultimately leading to better decision making by regulators and payers.
- 31 December 2019
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 35 (S1) , 94-95
VP90 Which Matching Adjusted Indirect Comparison Method Is Best?
Introduction: Matching adjusted indirect comparison (MAIC) methods are extremely useful when conducting ITCs, as they reduce baseline imbalances between studies, particularly upon patient characteristics that are confounded with treatment. The standard approach when conducting MAIC is that proposed by Signorovitch et al. (2010). However, there are newer, and potentially better, methods available.Methods: Three different MAIC methods (Signorovitch, Entropy Balancing, Polynomial Weighting) were compared using multiple phase 3 RCTs conducted in Diabetic Retinal Edema. The matching ability of each method was assessed, alongside its ability to avoid large weights (i.e. avoiding high leverage), and maximise effective same size (ESS). Each method's overall ease of use and impact upon estimates of treatment effectiveness were also evaluated.Results: All methods were able to precisely match the aggregate level data. However, the Entropy Balancing and Polynomial Weighting both outperformed the Signorovitch method in terms of having the lowest maximum weights. The Polynomial Weighting provided the highest ESS. The Entropy Balancing method was arguably the most challenging to implement, whilst the Signorovitch method the least. The Polynomial Weighting method appears to provide the greatest flexibility to the user.Conclusions: Whilst the Signorovitch method has become almost synonymous with MAIC, the Entropy Balancing and Polynomial Weighting methods offer potentially superior performance. In the absence of head-to-head trial data, these new MAIC approaches should provide less biased and more precise estimates of comparative effectiveness – ultimately leading to better decision making by regulators and payers.
- Open Access
- 5 May 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (5) , e0173353
Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL
This study compared outcomes following fingolimod or BRACE treatments (beta-interferons/glatiramer acetate) in patients with active MS (≥ 1 relapse in the previous year) following previous BRACE treatment. Patients with active MS who previously received BRACE were identified from German prospective, observational studies, PANGAEA and PEARL. A novel methodology was developed to compare outcomes between propensity-score-matched cohorts (3:1 ratio) from the independent single-arm studies. Patients in PANGAEA (n = 1287) experienced 48% fewer relapses per year than those in PEARL (n = 429; annualized relapse rate ratio: 0.52; p < 0.001). The risk of 3-month or 6-month confirmed disability progression (CDP) was reduced in PANGAEA versus PEARL (3-month: 37% reduction; hazard ratio [HR], 0.63; p < 0.001; 6-month: 47% reduction; HR, 0.53; p < 0.001). A higher proportion of patients in PANGAEA (n = 1234) than PEARL (n = 401) were free from relapses and 3-month (65.7% vs 38.7%; p < 0.001) or 6-month (68.2% vs 39.2%; p < 0.001) CDP. The probability of confirmed disability improvement was higher in PANGAEA (n = 1163) than PEARL (n = 372; 3-month: 175% increase; HR, 2.75; p < 0.001; 6-month: 126% increase; HR, 2.26; p < 0.001). Patients in PANGAEA (n = 149) were less likely than those in PEARL (n = 307) to have taken sick leave (proportion with 0 days off work: 62.4% vs 44.6%; p = 0.0005). For change in disease severity from baseline (assessed by clinicians using the Clinical Global Impressions scale; PANGAEA, n = 1207; PEARL, n = 427), a larger proportion of patients had subjective improvement and a smaller proportion had worsening status in PANGAEA than PEARL (improvement: 28.2% vs 15.2%; worsening: 16.4% vs 30.4%; p < 0.0001). Fingolimod appears to be more effective than BRACE in improving clinical and physician-/patient-reported outcomes in individuals with active MS.
- 5 May 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (5) , e0173353
Open AccessTwo studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL
This study compared outcomes following fingolimod or BRACE treatments (beta-interferons/glatiramer acetate) in patients with active MS (≥ 1 relapse in the previous year) following previous BRACE treatment. Patients with active MS who previously received BRACE were identified from German prospective, observational studies, PANGAEA and PEARL. A novel methodology was developed to compare outcomes between propensity-score-matched cohorts (3:1 ratio) from the independent single-arm studies. Patients in PANGAEA (n = 1287) experienced 48% fewer relapses per year than those in PEARL (n = 429; annualized relapse rate ratio: 0.52; p < 0.001). The risk of 3-month or 6-month confirmed disability progression (CDP) was reduced in PANGAEA versus PEARL (3-month: 37% reduction; hazard ratio [HR], 0.63; p < 0.001; 6-month: 47% reduction; HR, 0.53; p < 0.001). A higher proportion of patients in PANGAEA (n = 1234) than PEARL (n = 401) were free from relapses and 3-month (65.7% vs 38.7%; p < 0.001) or 6-month (68.2% vs 39.2%; p < 0.001) CDP. The probability of confirmed disability improvement was higher in PANGAEA (n = 1163) than PEARL (n = 372; 3-month: 175% increase; HR, 2.75; p < 0.001; 6-month: 126% increase; HR, 2.26; p < 0.001). Patients in PANGAEA (n = 149) were less likely than those in PEARL (n = 307) to have taken sick leave (proportion with 0 days off work: 62.4% vs 44.6%; p = 0.0005). For change in disease severity from baseline (assessed by clinicians using the Clinical Global Impressions scale; PANGAEA, n = 1207; PEARL, n = 427), a larger proportion of patients had subjective improvement and a smaller proportion had worsening status in PANGAEA than PEARL (improvement: 28.2% vs 15.2%; worsening: 16.4% vs 30.4%; p < 0.0001). Fingolimod appears to be more effective than BRACE in improving clinical and physician-/patient-reported outcomes in individuals with active MS.
- Open Access
- 1 November 2016
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 5 (6) , 569-579
The mixed randomized trial: combining randomized, pragmatic and observational clinical trial designs
Clinical trial designs often fail to deliver data that jointly satisfy evolving demands of both regulatory and reimbursement authorities. We propose a new multi-tiered trial design to integrate efficacy and effectiveness, and address the evolving needs of authorities. The mixed randomized trial allocates patients first to trial arm – randomized controlled, pragmatic (randomized) or observational – and then to treatment group – experimental, placebo, active comparator, best available therapy or standard of care. Trial arms may be staggered over time to reflect the current state of randomized and non-randomized data of the experimental drug, and thereby still prioritize safety. At the same time, the mixed randomized trial allows for the collection of real-world data in a randomized setting, and thereby reduces selection bias.
- 1 November 2016
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 5 (6) , 569-579
Open AccessThe mixed randomized trial: combining randomized, pragmatic and observational clinical trial designs
Clinical trial designs often fail to deliver data that jointly satisfy evolving demands of both regulatory and reimbursement authorities. We propose a new multi-tiered trial design to integrate efficacy and effectiveness, and address the evolving needs of authorities. The mixed randomized trial allocates patients first to trial arm – randomized controlled, pragmatic (randomized) or observational – and then to treatment group – experimental, placebo, active comparator, best available therapy or standard of care. Trial arms may be staggered over time to reflect the current state of randomized and non-randomized data of the experimental drug, and thereby still prioritize safety. At the same time, the mixed randomized trial allows for the collection of real-world data in a randomized setting, and thereby reduces selection bias.
- 6 April 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (14_supplem)
Time Off From Work: a Matched Comparison of Fingolimod and BRACE in Patients with Multiple Sclerosis from the PANGAEA and PEARL Studies (P7.019)
- 6 April 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (14_supplem)
Time Off From Work: a Matched Comparison of Fingolimod and BRACE in Patients with Multiple Sclerosis from the PANGAEA and PEARL Studies (P7.019)
- 12 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (7_suppleme)
Effect of Fingolimod in Patients with No Disability as Measured by EDSS at Baseline: Post-Hoc Analyses of FREEDOMS I and II (P07.124)
- 12 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (7_suppleme)
Effect of Fingolimod in Patients with No Disability as Measured by EDSS at Baseline: Post-Hoc Analyses of FREEDOMS I and II (P07.124)
- Open Access
- 1 June 1999
- Published by BMJ in Injury Prevention
- Vol. 5 (2) , 114-118
Achieving compliance with pool fencing legislation in New Zealand: a survey of regulatory authorities
Objectives—To identify the status of compliance and enforcement of New Zealand's Fencing of Swimming Pools Act (FOSP Act), 10 years after its introduction, and to identify methods for improving both compliance with the act and the process of enforcement.Methods—A postal questionnaire was sent to all 74 authorities in New Zealand in which they were asked questions about their enforcement of the FOSP Act. Semistructured telephone interviews were conducted with 12 authorities to supplement the data obtained in the postal survey.Results—Based on responses to the survey, it was estimated that there are over 59 000 domestic swimming pools in New Zealand, giving rates of 46 pools/1000 dwellings and 16 pools/1000 persons. The authorities reported that 44% of pools complied with the act, and a further 4% had been granted exemptions. Nineteen per cent of pools were reported to not comply with the act, and the compliance status of a further 33% was not known, or not stated by the authority. Only 9% of authorities had procedures for locating and inspecting pools, while 28% had a programme of reinspection to ensure that pools continued to comply. Pool owner resistance was considered to be the main difficulty with enforcing the act, and nearly half of the authorities believed publicity or education was needed to overcome these barriers. Fifty two per cent of authorities had publicised the act during the 12 months preceding the survey.Conclusions—Due to ambiguities within the legislation, and differing levels of commitment by authorities to locate pools and monitor compliance, compliance with the FOSP Act is not consistent nationally. If the act were less ambiguous, there would be greater consistency and more enforcement.
- 1 June 1999
- Published by BMJ in Injury Prevention
- Vol. 5 (2) , 114-118
Open AccessAchieving compliance with pool fencing legislation in New Zealand: a survey of regulatory authorities
Objectives—To identify the status of compliance and enforcement of New Zealand's Fencing of Swimming Pools Act (FOSP Act), 10 years after its introduction, and to identify methods for improving both compliance with the act and the process of enforcement.Methods—A postal questionnaire was sent to all 74 authorities in New Zealand in which they were asked questions about their enforcement of the FOSP Act. Semistructured telephone interviews were conducted with 12 authorities to supplement the data obtained in the postal survey.Results—Based on responses to the survey, it was estimated that there are over 59 000 domestic swimming pools in New Zealand, giving rates of 46 pools/1000 dwellings and 16 pools/1000 persons. The authorities reported that 44% of pools complied with the act, and a further 4% had been granted exemptions. Nineteen per cent of pools were reported to not comply with the act, and the compliance status of a further 33% was not known, or not stated by the authority. Only 9% of authorities had procedures for locating and inspecting pools, while 28% had a programme of reinspection to ensure that pools continued to comply. Pool owner resistance was considered to be the main difficulty with enforcing the act, and nearly half of the authorities believed publicity or education was needed to overcome these barriers. Fifty two per cent of authorities had publicised the act during the 12 months preceding the survey.Conclusions—Due to ambiguities within the legislation, and differing levels of commitment by authorities to locate pools and monitor compliance, compliance with the FOSP Act is not consistent nationally. If the act were less ambiguous, there would be greater consistency and more enforcement.